Bio-Gene Technology logo

Bio-Gene Technology(ASX) BGT

Market CapA$6.13MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)-92%
5 Year-91%
1 Year-59%
1 Month-18%
A$0.01
+0.00%
+0.00Today
Bio-Gene Technology last closing stock price
MetricPriceDate
Last closeAUD 0.012026-10-08
Bio-Gene Technology stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-12.5%AUD 0.022026-09-30
1 month-17.65%AUD 0.022026-09-08
3 month-17.65%AUD 0.022026-07-10
Year to date-39.13%AUD 0.022025-12-29
1 year-58.82%AUD 0.032025-10-08
3 year-80%AUD 0.072023-10-09
5 year-90.51%AUD 0.152021-10-08
Since inception-92%AUD 0.202017-11-29

Bio-Gene Technology Financials at a Glance

Market Cap

A$6.13MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$0.00

Net Income (TTM)

-A$4.36M

EPS (TTM)

-A$0.01

P/E Ratio

-1.87

Dividend

A$0.00

Beta (Volatility)

-0.08 (Low)

Price

A$0.01

Volume

629,147

Open

A$0.01

Previous Close

A$0.01

Daily Range

A$0.01 - A$0.02

52-Week Range

A$0.01 - A$0.05

Estimated Earnings Date

Mar 3, 2027

BGT News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Bio-Gene Technology

Bio-Gene Technology Limited is an Australian agricultural technology firm focused on developing and commercializing innovative insecticides and pesticides. The company aims to provide effective solutions for animal health, crop protection, public health, and consumer applications.

Products and Services
  • Flavocide, an insecticide utilizing beta-triketone technology
  • Qcide, a natural oil derived from eucalyptus cloeziana
  • Research partnerships for developing advanced agricultural solutions
Growth Outlook
  • Partnerships with BASF and other organizations enhance product effectiveness
  • Research collaboration with James Cook University supports future production
  • Focus on expanding market reach in agricultural inputs sector
Financial Highlights
  • Recent quarterly net income of -930,118 AUD reflects ongoing investment in R&D
  • Cash and cash equivalents of 1,939,590 AUD provide operational liquidity
  • Current ratio of 4.78 indicates strong short-term financial health
Bio-Gene Technology Limited operates in a competitive agricultural inputs market, leveraging innovative technologies to address pest control challenges. The company's flagship products, Flavocide and Qcide, are designed to meet the growing demand for sustainable agricultural solutions. With strategic partnerships and a commitment to research and development, Bio-Gene is positioned to capitalize on emerging opportunities in the sector. Recent financial data indicates a focus on long-term growth, despite current net losses, highlighting the company's dedication to innovation and market expansion.
AI Generated • Oct 7, 2026

Industry

Chemicals

Sector

Materials

CEO

Tim Grogan

Website

bio-gene.com.au

Headquarters

Melbourne, VIC 3000, AU

BGT Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-143.11%

Return on Capital

-162.96%

Return on Assets

-89.29%

Earnings Yield

-53.48%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$6.13MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

438.06M

Volume

629.15K

Avg. Volume

193.10K

Financials (TTM)

Gross Profit

-A$497.26K

Operating Income

-A$6.50M

EBITDA

-A$5.40M

Operating Cash Flow

-A$3.65M

Capital Expenditure

-A$4.00

Free Cash Flow

-A$3.65M

Cash & ST Invst.

A$1.94M

Total Debt

A$0.00

Bio-Gene Technology Performance Analysis

Bio-Gene Technology annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30AUD 149,232-66.5%
20242024-06-30AUD 18,320-87.7%
20252025-06-30AUD 0N/A
20262026-06-30AUD 0N/A
Bio-Gene Technology sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31100.0%
Q42025-06-30N/A
Q22025-12-31N/A
Q42026-06-30N/A
Bio-Gene Technology annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30AUD -0.02-3.2%
20242024-06-30AUD -0.01-29.3%
20252025-06-30AUD -0.01-6.2%
20262026-06-30AUD -0.01-38.5%
Bio-Gene Technology sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31-55.3%
Q42025-06-3065.8%
Q22025-12-31-84.0%
Q42026-06-3037.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

A$0.00

+100.0%

Gross Profit

-A$21.15K

+83.7%

Gross Margin

0.00%

N/A

Market Cap

A$6.13MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$1.23M

N/A

Employees

5

N/A

Net Income

-A$930.12K

-3.4%

EBITDA

-A$598.23K

+35.3%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

A$1.94M

-12.2%

Total Debt

A$0.00

N/A

Accounts Receivable

A$407.64K

-22.2%

Inventory

A$0.00

N/A

Long Term Debt

A$0.00

N/A

Short Term Debt

A$0.00

N/A

Return on Assets

-89.29%

N/A

Return on Invested Capital

-1.63%

N/A

Free Cash Flow

-A$992.10K

+2.1%

Operating Cash Flow

-A$992.10K

+1.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ACR.AXAcrux Limited
A$0.01+10.00%
VBS.AXVectus Biosystems Limited
A$0.11+0.00%
PER.AXPercheron Therapeutics Limited
A$0.00+0.00%
CAN.AXCann Group Limited
A$0.01+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
VEEAVeea
$6.09+57.36%
TAT&T
$23.04-6.33%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$34.04+0.74%
SPCXSpace Exploration Technologies
$163.11+1.58%

Questions About BGT

What is the current price of Bio-Gene Technology?

Bio-Gene Technology is trading at A$0.01 per share.

What is the 52-week range for Bio-Gene Technology?

Over the past 52 weeks, Bio-Gene Technology has traded between A$0.01 and A$0.05.

How much debt does Bio-Gene Technology have?

As of the most recent reporting period, Bio-Gene Technology reported total debt of A$0.00.

How much cash does Bio-Gene Technology have on hand?

Bio-Gene Technology reported A$1.94M in cash and cash equivalents in its most recent financial results.

What is Bio-Gene Technology’s dividend yield?

Bio-Gene Technology does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services